Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study.

Staaf J, Glodzik D, Bosch A, Vallon-Christersson J, Reuterswärd C, Häkkinen J, Degasperi A, Amarante TD, Saal LH, Hegardt C, Stobart H, Ehinger A, Larsson C, Rydén L, Loman N, Malmberg M, Kvist A, Ehrencrona H, Davies HR, Borg Å, Nik-Zainal S.

Nat Med. 2019 Sep 30. doi: 10.1038/s41591-019-0582-4. [Epub ahead of print]

PMID:
31570822
2.

Tumor Characteristics and Molecular Subtypes in Breast Cancer Screening with Digital Breast Tomosynthesis: The Malmö Breast Tomosynthesis Screening Trial.

Johnson K, Zackrisson S, Rosso A, Sartor H, Saal LH, Andersson I, Lång K.

Radiology. 2019 Nov;293(2):273-281. doi: 10.1148/radiol.2019190132. Epub 2019 Sep 3.

PMID:
31478799
3.

Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series.

Vallon-Christersson J, Häkkinen J, Hegardt C, Saal LH, Larsson C, Ehinger A, Lindman H, Olofsson H, Sjöblom T, Wärnberg F, Ryden L, Loman N, Malmberg M, Borg Å, Staaf J.

Sci Rep. 2019 Aug 21;9(1):12184. doi: 10.1038/s41598-019-48570-x.

4.

Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer.

Lundgren C, Bendahl PO, Borg Å, Ehinger A, Hegardt C, Larsson C, Loman N, Malmberg M, Olofsson H, Saal LH, Sjöblom T, Lindman H, Klintman M, Häkkinen J, Vallon-Christersson J, Fernö M, Rydén L, Ekholm M.

Breast Cancer Res Treat. 2019 Nov;178(2):459-467. doi: 10.1007/s10549-019-05378-7. Epub 2019 Aug 20.

PMID:
31432367
5.

Prediction of Lymph Node Metastasis in Breast Cancer by Gene Expression and Clinicopathological Models: Development and Validation within a Population-Based Cohort.

Dihge L, Vallon-Christersson J, Hegardt C, Saal LH, Häkkinen J, Larsson C, Ehinger A, Loman N, Malmberg M, Bendahl PO, Borg Å, Staaf J, Rydén L.

Clin Cancer Res. 2019 Jul 24. doi: 10.1158/1078-0432.CCR-19-0075. [Epub ahead of print]

PMID:
31340938
6.

Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment.

Förnvik D, Aaltonen KE, Chen Y, George AM, Brueffer C, Rigo R, Loman N, Saal LH, Rydén L.

Breast Cancer Res Treat. 2019 Sep;177(2):447-455. doi: 10.1007/s10549-019-05326-5. Epub 2019 Jun 24.

7.

Pre-operative plasma cell-free circulating tumor DNA and serum protein tumor markers as predictors of lung adenocarcinoma recurrence.

Isaksson S, George AM, Jönsson M, Cirenajwis H, Jönsson P, Bendahl PO, Brunnström H, Staaf J, Saal LH, Planck M.

Acta Oncol. 2019 Aug;58(8):1079-1086. doi: 10.1080/0284186X.2019.1610573. Epub 2019 Jun 24.

PMID:
31230502
8.

Identification and Use of Personalized Genomic Markers for Monitoring Circulating Tumor DNA.

Chen Y, George AM, Olsson E, Saal LH.

Methods Mol Biol. 2018;1768:303-322. doi: 10.1007/978-1-4939-7778-9_17.

PMID:
29717450
9.

Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling.

Roswall P, Bocci M, Bartoschek M, Li H, Kristiansen G, Jansson S, Lehn S, Sjölund J, Reid S, Larsson C, Eriksson P, Anderberg C, Cortez E, Saal LH, Orsmark-Pietras C, Cordero E, Haller BK, Häkkinen J, Burvenich IJG, Lim E, Orimo A, Höglund M, Rydén L, Moch H, Scott AM, Eriksson U, Pietras K.

Nat Med. 2018 May;24(4):463-473. doi: 10.1038/nm.4494. Epub 2018 Mar 12.

10.

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.

Zardavas D, Te Marvelde L, Milne RL, Fumagalli D, Fountzilas G, Kotoula V, Razis E, Papaxoinis G, Joensuu H, Moynahan ME, Hennessy BT, Bieche I, Saal LH, Stal O, Iacopetta B, Jensen JD, O'Toole S, Lopez-Knowles E, Barbaraeschi M, Noguchi S, Azim HA Jr, Lerma E, Bachelot T, Wang Q, Perez-Tenorio G, Can de Velde CJH, Rea DW, Sabine V, Bartlett JMS, Sotiriou C, Michiels S, Loi S.

J Clin Oncol. 2018 Apr 1;36(10):981-990. doi: 10.1200/JCO.2017.74.8301. Epub 2018 Feb 22.

11.

Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative.

Rydén L, Loman N, Larsson C, Hegardt C, Vallon-Christersson J, Malmberg M, Lindman H, Ehinger A, Saal LH, Borg Å.

Br J Surg. 2018 Jan;105(2):e158-e168. doi: 10.1002/bjs.10741.

12.

Germline mutations in BRCA1 and BRCA2 incidentally revealed in a biobank research study: experiences from re-contacting mutation carriers and relatives.

Nilsson MP, Emmertz M, Kristoffersson U, Borg Å, Larsson C, Rehn M, Winter C, Saal LH, Brandberg Y, Loman N.

J Community Genet. 2018 Jul;9(3):201-208. doi: 10.1007/s12687-017-0341-5. Epub 2017 Oct 30.

13.

p53 Maintains Baseline Expression of Multiple Tumor Suppressor Genes.

Pappas K, Xu J, Zairis S, Resnick-Silverman L, Abate F, Steinbach N, Ozturk S, Saal LH, Su T, Cheung P, Schmidt H, Aaronson S, Hibshoosh H, Manfredi J, Rabadan R, Parsons R.

Mol Cancer Res. 2017 Aug;15(8):1051-1062. doi: 10.1158/1541-7786.MCR-17-0089. Epub 2017 May 8.

14.

NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics.

Cirenajwis H, Lauss M, Ekedahl H, Törngren T, Kvist A, Saal LH, Olsson H, Staaf J, Carneiro A, Ingvar C, Harbst K, Hayward NK, Jönsson G.

Mol Oncol. 2017 Apr;11(4):438-451. doi: 10.1002/1878-0261.12050. Epub 2017 Mar 24.

15.

Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer.

Nilsson MP, Winter C, Kristoffersson U, Rehn M, Larsson C, Saal LH, Loman N.

Fam Cancer. 2017 Apr;16(2):187-193. doi: 10.1007/s10689-016-9953-x.

16.

International Interlaboratory Digital PCR Study Demonstrating High Reproducibility for the Measurement of a Rare Sequence Variant.

Whale AS, Devonshire AS, Karlin-Neumann G, Regan J, Javier L, Cowen S, Fernandez-Gonzalez A, Jones GM, Redshaw N, Beck J, Berger AW, Combaret V, Dahl Kjersgaard N, Davis L, Fina F, Forshew T, Fredslund Andersen R, Galbiati S, González Hernández Á, Haynes CA, Janku F, Lacave R, Lee J, Mistry V, Pender A, Pradines A, Proudhon C, Saal LH, Stieglitz E, Ulrich B, Foy CA, Parkes H, Tzonev S, Huggett JF.

Anal Chem. 2017 Feb 7;89(3):1724-1733. doi: 10.1021/acs.analchem.6b03980. Epub 2017 Jan 18.

PMID:
27935690
17.
18.

Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.

She QB, Gruvberger-Saal SK, Maurer M, Chen Y, Jumppanen M, Su T, Dendy M, Lau YK, Memeo L, Horlings HM, van de Vijver MJ, Isola J, Hibshoosh H, Rosen N, Parsons R, Saal LH.

BMC Cancer. 2016 Aug 2;16:587. doi: 10.1186/s12885-016-2609-2.

19.

Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic.

Winter C, Nilsson MP, Olsson E, George AM, Chen Y, Kvist A, Törngren T, Vallon-Christersson J, Hegardt C, Häkkinen J, Jönsson G, Grabau D, Malmberg M, Kristoffersson U, Rehn M, Gruvberger-Saal SK, Larsson C, Borg Å, Loman N, Saal LH.

Ann Oncol. 2016 Aug;27(8):1532-8. doi: 10.1093/annonc/mdw209. Epub 2016 May 18.

20.

TopHat-Recondition: a post-processor for TopHat unmapped reads.

Brueffer C, Saal LH.

BMC Bioinformatics. 2016 May 4;17(1):199. doi: 10.1186/s12859-016-1058-x.

21.

Apparent exchange rate for breast cancer characterization.

Lasič S, Oredsson S, Partridge SC, Saal LH, Topgaard D, Nilsson M, Bryskhe K.

NMR Biomed. 2016 May;29(5):631-9. doi: 10.1002/nbm.3504. Epub 2016 Feb 29.

22.

Mutation Screening of 1,237 Cancer Genes across Six Model Cell Lines of Basal-Like Breast Cancer.

Olsson E, Winter C, George A, Chen Y, Törngren T, Bendahl PO, Borg Å, Gruvberger-Saal SK, Saal LH.

PLoS One. 2015 Dec 15;10(12):e0144528. doi: 10.1371/journal.pone.0144528. eCollection 2015.

23.

Remarkable similarities of chromosomal rearrangements between primary human breast cancers and matched distant metastases as revealed by whole-genome sequencing.

Tang MH, Dahlgren M, Brueffer C, Tjitrowirjo T, Winter C, Chen Y, Olsson E, Wang K, Törngren T, Sjöström M, Grabau D, Bendahl PO, Rydén L, Niméus E, Saal LH, Borg Å, Gruvberger-Saal SK.

Oncotarget. 2015 Nov 10;6(35):37169-84. doi: 10.18632/oncotarget.5951.

24.

Expression of functional toll like receptor 4 in estrogen receptor/progesterone receptor-negative breast cancer.

Mehmeti M, Allaoui R, Bergenfelz C, Saal LH, Ethier SP, Johansson ME, Jirström K, Leandersson K.

Breast Cancer Res. 2015 Sep 22;17:130. doi: 10.1186/s13058-015-0640-x.

25.

PTEN and NEDD4 in Human Breast Carcinoma.

Chen Y, van de Vijver MJ, Hibshoosh H, Parsons R, Saal LH.

Pathol Oncol Res. 2016 Jan;22(1):41-7. doi: 10.1007/s12253-015-9971-2. Epub 2015 Aug 15.

26.

Contralateral breast cancer can represent a metastatic spread of the first primary tumor: determination of clonal relationship between contralateral breast cancers using next-generation whole genome sequencing.

Alkner S, Tang MH, Brueffer C, Dahlgren M, Chen Y, Olsson E, Winter C, Baker S, Ehinger A, Rydén L, Saal LH, Fernö M, Gruvberger-Saal SK.

Breast Cancer Res. 2015 Aug 5;17:102. doi: 10.1186/s13058-015-0608-x.

27.

Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease.

Olsson E, Winter C, George A, Chen Y, Howlin J, Tang MH, Dahlgren M, Schulz R, Grabau D, van Westen D, Fernö M, Ingvar C, Rose C, Bendahl PO, Rydén L, Borg Å, Gruvberger-Saal SK, Jernström H, Saal LH.

EMBO Mol Med. 2015 Aug;7(8):1034-47. doi: 10.15252/emmm.201404913.

28.

Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy.

Cirenajwis H, Ekedahl H, Lauss M, Harbst K, Carneiro A, Enoksson J, Rosengren F, Werner-Hartman L, Törngren T, Kvist A, Fredlund E, Bendahl PO, Jirström K, Lundgren L, Howlin J, Borg Å, Gruvberger-Saal SK, Saal LH, Nielsen K, Ringnér M, Tsao H, Olsson H, Ingvar C, Staaf J, Jönsson G.

Oncotarget. 2015 May 20;6(14):12297-309.

29.

The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine.

Saal LH, Vallon-Christersson J, Häkkinen J, Hegardt C, Grabau D, Winter C, Brueffer C, Tang MH, Reuterswärd C, Schulz R, Karlsson A, Ehinger A, Malina J, Manjer J, Malmberg M, Larsson C, Rydén L, Loman N, Borg Å.

Genome Med. 2015 Feb 2;7(1):20. doi: 10.1186/s13073-015-0131-9. eCollection 2015.

30.

Molecular and genetic diversity in the metastatic process of melanoma.

Harbst K, Lauss M, Cirenajwis H, Winter C, Howlin J, Törngren T, Kvist A, Nodin B, Olsson E, Häkkinen J, Jirström K, Staaf J, Lundgren L, Olsson H, Ingvar C, Gruvberger-Saal SK, Saal LH, Jönsson G.

J Pathol. 2014 May;233(1):39-50. doi: 10.1002/path.4318. Epub 2014 Jan 27.

31.

Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells.

Pires MM, Hopkins BD, Saal LH, Parsons RE.

Cancer Biol Ther. 2013 Mar;14(3):246-53. doi: 10.4161/cbt.23297. Epub 2013 Jan 4.

32.

Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes.

Holm K, Grabau D, Lövgren K, Aradottir S, Gruvberger-Saal S, Howlin J, Saal LH, Ethier SP, Bendahl PO, Stål O, Malmström P, Fernö M, Rydén L, Hegardt C, Borg Å, Ringnér M.

Mol Oncol. 2012 Oct;6(5):494-506. doi: 10.1016/j.molonc.2012.06.002. Epub 2012 Jun 20.

33.

The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer.

Jönsson G, Staaf J, Vallon-Christersson J, Ringnér M, Gruvberger-Saal SK, Saal LH, Holm K, Hegardt C, Arason A, Fagerholm R, Persson C, Grabau D, Johnsson E, Lövgren K, Magnusson L, Heikkilä P, Agnarsson BA, Johannsson OT, Malmström P, Fernö M, Olsson H, Loman N, Nevanlinna H, Barkardottir RB, Borg Å.

Cancer Res. 2012 Aug 15;72(16):4028-36. Epub 2012 Jun 15.

34.

CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers.

Olsson E, Honeth G, Bendahl PO, Saal LH, Gruvberger-Saal S, Ringnér M, Vallon-Christersson J, Jönsson G, Holm K, Lövgren K, Fernö M, Grabau D, Borg A, Hegardt C.

BMC Cancer. 2011 Sep 29;11:418. doi: 10.1186/1471-2407-11-418.

35.

Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a.

Fine B, Hodakoski C, Koujak S, Su T, Saal LH, Maurer M, Hopkins B, Keniry M, Sulis ML, Mense S, Hibshoosh H, Parsons R.

Science. 2009 Sep 4;325(5945):1261-5. doi: 10.1126/science.1173569.

36.

3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma.

Maurer M, Su T, Saal LH, Koujak S, Hopkins BD, Barkley CR, Wu J, Nandula S, Dutta B, Xie Y, Chin YR, Kim DI, Ferris JS, Gruvberger-Saal SK, Laakso M, Wang X, Memeo L, Rojtman A, Matos T, Yu JS, Cordon-Cardo C, Isola J, Terry MB, Toker A, Mills GB, Zhao JJ, Murty VV, Hibshoosh H, Parsons R.

Cancer Res. 2009 Aug 1;69(15):6299-306. doi: 10.1158/0008-5472.CAN-09-0820. Epub 2009 Jul 14.

37.

The CD44+/CD24- phenotype is enriched in basal-like breast tumors.

Honeth G, Bendahl PO, Ringnér M, Saal LH, Gruvberger-Saal SK, Lövgren K, Grabau D, Fernö M, Borg A, Hegardt C.

Breast Cancer Res. 2008;10(3):R53. doi: 10.1186/bcr2108. Epub 2008 Jun 17.

38.

Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair.

Saal LH, Gruvberger-Saal SK, Persson C, Lövgren K, Jumppanen M, Staaf J, Jönsson G, Pires MM, Maurer M, Holm K, Koujak S, Subramaniyam S, Vallon-Christersson J, Olsson H, Su T, Memeo L, Ludwig T, Ethier SP, Krogh M, Szabolcs M, Murty VV, Isola J, Hibshoosh H, Parsons R, Borg A.

Nat Genet. 2008 Jan;40(1):102-7. Epub 2007 Dec 9.

39.

Microarray analysis of gliomas reveals chromosomal position-associated gene expression patterns and identifies potential immunotherapy targets.

Persson O, Krogh M, Saal LH, Englund E, Liu J, Parsons R, Mandahl N, Borg A, Widegren B, Salford LG.

J Neurooncol. 2007 Oct;85(1):11-24. Epub 2007 Jul 17.

PMID:
17634744
40.

Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.

Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, Koujak S, Ferrando AA, Malmström P, Memeo L, Isola J, Bendahl PO, Rosen N, Hibshoosh H, Ringnér M, Borg A, Parsons R.

Proc Natl Acad Sci U S A. 2007 May 1;104(18):7564-9. Epub 2007 Apr 23.

41.

Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.

Gruvberger-Saal SK, Bendahl PO, Saal LH, Laakso M, Hegardt C, Edén P, Peterson C, Malmström P, Isola J, Borg A, Fernö M.

Clin Cancer Res. 2007 Apr 1;13(7):1987-94.

42.

An introduction to BioArray Software Environment.

Troein C, Vallon-Christersson J, Saal LH.

Methods Enzymol. 2006;411:99-119. Review.

PMID:
16939788
43.

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.

Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmström PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, Parsons R.

Cancer Res. 2005 Apr 1;65(7):2554-9.

44.

BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data.

Saal LH, Troein C, Vallon-Christersson J, Gruvberger S, Borg A, Peterson C.

Genome Biol. 2002 Jul 15;3(8):SOFTWARE0003. Epub 2002 Jul 15.

45.

Gene expression profiling in cancer using cDNA microarrays.

Khan J, Saal LH, Bittner ML, Jiang Y, Gooden GC, Glatfelter AA, Meltzer PS.

Methods Mol Med. 2002;68:205-22. No abstract available.

PMID:
11901504
46.

Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns.

Gruvberger S, Ringnér M, Chen Y, Panavally S, Saal LH, Borg A, Fernö M, Peterson C, Meltzer PS.

Cancer Res. 2001 Aug 15;61(16):5979-84.

47.

Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks.

Khan J, Wei JS, Ringnér M, Saal LH, Ladanyi M, Westermann F, Berthold F, Schwab M, Antonescu CR, Peterson C, Meltzer PS.

Nat Med. 2001 Jun;7(6):673-9.

48.

cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene.

Khan J, Bittner ML, Saal LH, Teichmann U, Azorsa DO, Gooden GC, Pavan WJ, Trent JM, Meltzer PS.

Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13264-9.

49.

Expression profiling in cancer using cDNA microarrays.

Khan J, Saal LH, Bittner ML, Chen Y, Trent JM, Meltzer PS.

Electrophoresis. 1999 Feb;20(2):223-9. Review.

PMID:
10197427

Supplemental Content

Support Center